Bristol-Myers Squibb CoChange company Symbol lookupSelect an option...BMY Bristol-Myers Squibb CoGMVD G Medical Innovations Holdings LtdCMPX Compass Therapeutics Inc.AMST Amesite IncAMPX Amprius Technologies IncPRTK Paratek Pharmaceuticals IncEGRAY Energy Resources Of Australia LtdIVAC Intevac IncPFE Pfizer IncBNOX Bionomics LtdGo
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
|
|
|
|
| |
Company Profile
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
Valuation Ratios
- Price/Earnings (TTM)
- 23.48x
- Price/Sales (TTM)
- 3.16x
- Price/Book (MRQ)
- 4.63x
- Price/Cash Flow (TTM)
- 8.77x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Giovanni CaforioChmn.
- David V. ElkinsCFO
- Ann M. Powell
- Greg MeyersExec.VP
- Sandra LeungExec.VP
Address
- 430 E. 29Th Street, 14 Floor
- New York, NY 10016
- Phone: (212) 546-4000
- Fax: (302) 655-5049
- https://www.bms.com/
Insider Trading
During the most recent quarter, 313K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.